American Journal of Physiology-Heart and Circulatory Physiology · 2009 · 54 citations · 26 references
MedicineCardiologyPharmacologyBiochemical PharmacologyExperimental PharmacologyMolecular PharmacologyCardiac PharmacotherapyCardiovascular PharmacologyCoronary Artery DiseaseRabbit PharmacologyAntidiabetic Drug TherapyInsulin-sensitizing TherapyMitochondrial Atp ProductionMyocardial Infarction PharmacotherapyPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated ReceptorsPost-myocardial Infarction PharmacotherapyRabbit Models
The insulin-sensitizing drug pioglitazone has been reported to be protective against myocardial infarction. However, its precise mechanism is unclear. Rabbits underwent 30 min of coronary occlusion followed by 48 h of reperfusion. Rabbits were assigned randomly to nine groups (n = 10 in each): the control group (fed a normal diet), pioglitazone group (fed diets containing 1 mg.kg(-1).day(-1) pioglitazone), pioglitazone + 5-hydroxydecanoic acid (HD) group [fed the pioglitazone diet + 5 mg/kg iv 5-HD, a mitochondrial ATP-sensitive K(+) (K(ATP)) channel blocker], pioglitazone + GW9662 group [fed the pioglitazone diet + 2 mg/kg iv GW9662, a peroxisome proliferator activated receptor (PPAR)-gamma antagonist], GW9662 group (fed a normal diet + iv GW9662), pioglitazone + wortmannin group [fed the pioglitazone diet + 0.6 mg/kg iv wortmannin, a phosphatidylinositol (PI)3-kinase inhibitor], wortmannin group (fed a normal diet + iv wortmannin), pioglitazone + nitro-l-arginine methyl ester (l-NAME) group [fed the pioglitazone diet + 10 mg/kg iv l-NAME, a nitric oxide synthase (NOS) inhibitor], and l-NAME group (fed a normal diet + iv l-NAME). All groups were fed the diets for 7 days. The risk area and nonrisk area of the left ventricle (LV) were separated by Evans blue dye, and the infarct area was determined by triphenyltetrazolium chloride staining. The infarct size was calculated as a percentage of the LV risk area. Western blotting was performed to assess levels of Akt and phospho-Akt and phospho-endothelial NOS (eNOS) in the myocardium following reperfusion. The infarct size was significantly smaller in the pioglitazone group (21 +/- 2%) than in the control group (43 +/- 3%). This effect was abolished by GW9662 (42 +/- 3%), wortmannin (40 +/- 3%), or l-NAME (42 +/- 7%) but not by 5-HD (24 +/- 5%). Western blotting showed higher levels of phospho-Akt and phospho-eNOS in the pioglitazone group. Pioglitazone reduces the myocardial infarct size via activation of PPAR-gamma, PI3-kinase, Akt, and eNOS pathways, but not via opening the mitochondrial K(ATP) channel. Pioglitazone may be a novel strategy for the treatment of diabetes mellitus with coronary artery disease.
26
John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text
Diabetes and cardiovascular disease. The Framingham study
William B. Kannel · JAMA · 1979 · 4K citations
Medicine, Cardiology, Endocrinology +17
Diabetes and Cardiovascular Disease
William B. Kannel · JAMA · 1979 · 2.8K citations
Role of Bradykinin in Protection of Ischemic Preconditioning in Rabbit Hearts
Mahiko Goto, Yongge Liu, Xi‐Ming Yang et al. · Circulation Research · 1995 · 526 citations
Medicine, Cardiology, Pharmacology +11